DSIP — Research Overview
Chemical Name: Delta Sleep-Inducing Peptide Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (nonapeptide) Molecular Weight: 850 daltons Discovery: First isolated from rabbit cerebral venous blood in 1977 by the Schoenenberger-Monnier group in Basel, Switzerland Distribution: Found in both free and bound forms in the hypothalamus, limbic system, and pituitary as well as peripheral organs, tissues, gut secretory cells, and pancreas Category: Endogenous neuromodulatory neuropeptide / multifunctional regulatory peptide
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is DSIP?
Delta sleep-inducing peptide (DSIP) is a naturally occurring nonapeptide first isolated from the cerebral venous blood of rabbits in 1977 following low-frequency electrical stimulation of the intralaminar thalamic nuclei. It was initially characterized as a candidate sleep-promoting factor based on its ability to induce delta-wave slow-wave sleep in the rabbit model from which it was isolated. The name reflects this original characterization, though subsequent research has revealed a substantially broader and more complex biological profile that extends well beyond sleep regulation.
DSIP has a unique amino acid sequence with no known homology to other characterized neuropeptide families, making it a structurally distinct research compound. It is an amphiphilic peptide capable of crossing the blood-brain barrier, which is relevant to its observed central nervous system effects. It has been detected in both free and bound forms across multiple tissues including the hypothalamus, limbic system, pituitary, gut secretory cells, and pancreas — where it co-localizes with glucagon — suggesting a role in multiple regulatory systems beyond the central nervous system.
Brain and plasma DSIP concentrations exhibit a marked diurnal variation, with concentrations characteristically lower in the mornings and higher in the afternoons. This circadian pattern in endogenous DSIP levels has been proposed as relevant to its relationship with sleep-wake cycling, though the causal direction of this relationship remains an area of active investigation.
An important note for researchers reviewing this literature: DSIP is one of the more scientifically complex and contested research compounds studied to date. The relationship between DSIP and sleep, despite the compound’s name, has never been fully characterized, and the evidence is genuinely mixed. No dedicated DSIP receptor has been identified. The gene encoding DSIP has not been isolated. Published research on DSIP spans a wide range of proposed biological activities, some of which are supported by multiple independent studies and some of which remain preliminary or contested. This post presents the published evidence accurately and includes appropriate context about the limitations of the current literature.
Mechanism of Action
DSIP does not act through a single characterized receptor pathway. No dedicated DSIP receptor has been identified in published research, which represents a significant gap in mechanistic understanding compared to more extensively studied peptides. Several mechanisms of action have been proposed and partially characterized based on experimental data.
NMDA receptor involvement: In the brain, DSIP’s actions may be partially mediated through NMDA glutamate receptors. NMDA receptor modulation is consistent with some of the neuroprotective and stress-limiting effects observed in preclinical models.
Monoamine oxidase modulation: DSIP has been shown to partially restrict stress-induced changes in the activity of mitochondrial monoamine oxidase type A (MAO-A) and serotonin levels in rat brain under hypoxic conditions. Some DSIP analogs with enhanced MAO-A modulating activity have been characterized.
Mitochondrial respiratory enhancement: Published research demonstrates that DSIP enhances the efficiency of oxidative phosphorylation in rat brain mitochondria in vitro, increasing the respiratory control ratio and the rate of ADP phosphorylation. Pretreatment with DSIP was shown to completely inhibit hypoxia-induced reduction of mitochondrial respiratory activity in rats, suggesting a cytoprotective mechanism relevant to stress resistance.
Corticotropin-releasing factor modulation: DSIP has been shown in some animal studies to reduce CRF-induced corticosterone release and to attenuate ACTH secretion, suggesting a stress-limiting role at the hypothalamic-pituitary-adrenal axis level. Evidence in human subjects on this point is inconsistent across studies.
Somatotropic axis effects: Research has reported that DSIP stimulates the release of somatoliberin and somatotropin secretion while inhibiting somatostatin secretion, potentially contributing to GH axis regulation — though this has not been the primary focus of clinical investigation.
Sleep modulation: DSIP has been described as a sleep-promoting substance rather than a classical sedative. Published clinical research describes it as having a modulating effect on sleep and wake functions with greater activity in circumstances where sleep is disturbed, and minimal effects in healthy subjects without sleep disturbance. A dose of DSIP given during the day has been reported to promote improved sleep on the subsequent night and for several nights thereafter — consistent with a modulatory rather than acutely sedating mechanism.
Published Research
Study 1 — Original Human Sleep Study: Acute and Delayed Effects
Authors: Schneider-Helmert D, Schoenenberger GA et al. Year: 1981 Journal: International Journal of Clinical Pharmacology and Toxicology PMID: 6895513 Full text: https://pubmed.ncbi.nlm.nih.gov/6895513/
This was the first study of DSIP administration to human subjects, conducted in six normal volunteers (four males, two females) in a double-blind crossover design with extensive psychophysiologic monitoring. DSIP was administered as a slow intravenous infusion at 25 nmol/kg in the morning.
Subjects immediately reported a feeling of sleep pressure following DSIP administration.
Total sleep time increased by 59% within a 130-minute interval after treatment compared to placebo.
Delayed effects on subsequent night sleep included shorter sleep onset, reduced percentage of stage 1 sleep, and better sleep efficiency.
Sophisticated behavioral and EEG analyses revealed no sedation in the classic pharmacological sense despite the increased sleep time, suggesting DSIP sustains natural sleep functions rather than inducing pharmacological sedation.
The authors concluded that DSIP in humans is efficacious by sustaining natural sleep functions, distinguishing it from conventional hypnotic agents.
Study 2 — Double-Blind Clinical Trial: Chronic Insomnia Patients
Authors: Bes F, Hofman W, Schuur J, Van Boxtel C Year: 1992 Journal: Neuropsychobiology PMID: 1299794 Full text: https://pubmed.ncbi.nlm.nih.gov/1299794/
This double-blind matched-pairs parallel-groups clinical study examined DSIP in 16 chronic insomnia patients across five consecutive nights in a laboratory setting. Half the patients received DSIP intravenously at 25 nmol/kg in the afternoon before nights 3, 4, and 5. Half received placebo.
Results for objective sleep quality measured by polysomnography indicated higher sleep efficiency and shorter sleep latency with DSIP compared to placebo.
One measure of subjectively estimated tiredness decreased within the DSIP group.
However the authors noted that statistically significant effects were weak and in part could be due to an incidental change in the placebo group.
None of the other measures including subjective sleep quality showed significant change.
The authors concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit, reflecting the mixed nature of the DSIP and sleep evidence base.
Study 3 — Stress Limiting Activity: MAO-A Modulation Under Hypoxia
Authors: Khvatova EM et al. Year: 1995 Journal: Peptides PMID: 7628639 Full text: https://pubmed.ncbi.nlm.nih.gov/7628639/
This preclinical study examined DSIP’s metabolic effects in rats subjected to short-term hypoxic stress conditions, focusing on mitochondrial monoamine oxidase type A activity and serotonin regulation in brain tissue.
DSIP partially restricted stress-induced changes in the activity of mitochondrial MAO-A and serotonin levels in rat brain under hypoxic conditions.
A number of DSIP analogs were tested and several compounds were identified with enhanced ability to counteract hypoxia-induced changes in MAO-A activity and serotonin content compared to the native neuropeptide.
This study established DSIP as a candidate stress-limiting neuropeptide operating through monoamine oxidase modulation and serotonin system regulation in brain tissue under metabolic stress.
Study 4 — Mitochondrial Respiratory Protection: Oxidative Phosphorylation
Authors: Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II Year: 2003 Journal: Peptides PMID: 12668217 Full text: https://pubmed.ncbi.nlm.nih.gov/12668217/
This study examined the influence of DSIP and Deltaran (a DSIP-based product) on oxidative phosphorylation and ATP production in rat brain mitochondria and brain homogenates under both normal and hypoxic conditions.
DSIP enhanced the respiratory control ratio and the rate of ADP phosphorylation in rat brain mitochondria, indicating improved efficiency of oxidative phosphorylation.
The same action was observed in rat brain homogenates.
Pretreatment of rats with DSIP at 120 micrograms per kilogram intraperitoneally prior to hypoxia exposure completely inhibited the hypoxia-induced reduction of mitochondrial respiratory activity, demonstrating a protective effect against metabolic stress at the cellular level.
The authors noted that neuromodulatory DSIP appears to be implicated in the attenuation of stress-induced pathological metabolic disturbances in various animal species and human beings, and that the capacity to enhance oxidative phosphorylation efficiency may contribute to understanding DSIP’s pronounced stress-protective and antioxidant effects in vivo.
Study 5 — Stroke Recovery: Motor Function in Rat Focal Stroke Model
Authors: Published in MDPI Molecules Year: 2021 Journal: MDPI Molecules Full text: https://www.mdpi.com/1420-3049/26/17/5173
This study investigated the effect of intranasal DSIP administration on motor function recovery following focal stroke induced by intraluminal middle cerebral artery occlusion in Sprague-Dawley rats. DSIP or vehicle was administered nasally at 120 micrograms per kilogram for 8 days — 60 minutes before occlusion and for 7 days after reperfusion. Motor coordination, balance, and bilateral asymmetry were assessed across 21 days of observation.
Although brain infarction volume in DSIP-treated animals was smaller than in vehicle-treated animals, the difference did not reach statistical significance.
Motor performance in the rotarod test significantly recovered in DSIP-treated animals compared to vehicle controls, demonstrating an effect on functional motor recovery that was not fully reflected in structural infarction volume measurements.
The authors attributed the motor recovery effect to possible rescuing of neurons in the motor cortex and subcortical structures associated with motor control, and to DSIP’s known effects on biosynthetic processes in the brain and monoamine oxidase system normalization.
The study adds to a body of preclinical evidence suggesting that DSIP may have neuroprotective properties beyond its originally characterized sleep-modulating activity.
Broader Research Areas Associated With DSIP
Published research across preclinical models has associated DSIP with the following additional biological activities. These represent areas of documented research interest though the evidence base varies considerably in strength across each area and most findings derive from animal models without human clinical replication.
Anticonvulsant activity: In rat models of metaphit-induced epilepsy, DSIP acted as an anticonvulsant, significantly decreasing the incidence and duration of seizures.
Analgesic effects: DSIP has been found to have an antinociceptive effect in mice when administered intracerebroventricularly or intracisternally, suggesting central pain modulation activity.
Geroprotective and anticarcinogenic research: In lifetime mouse studies, DSIP preparations decreased total spontaneous tumor incidence and produced geroprotective effects including slowing of age-related reproductive function decline, reduced chromosome aberration frequency in bone marrow, and increased maximum lifespan. These findings require substantial further investigation before any conclusions can be drawn.
Psychiatric research relevance: Plasma and cerebrospinal fluid concentrations of DSIP have been found to deviate from normal in patients with major depressive disorder in several studies, though the direction of the deviation and causal significance remain unclear.
Alzheimer’s disease: Levels of DSIP have been found to be slightly elevated in Alzheimer’s patients, though this is not considered likely to be causal based on current evidence.
An Important Limitation Note
DSIP presents a more complex and uncertain research profile than many other peptides on this site. Several limitations of the existing literature should be explicitly acknowledged.
No dedicated DSIP receptor has been identified. The mechanism by which DSIP exerts its effects remains incompletely characterized.
The DSIP gene has not been isolated, and it is unknown where DSIP is synthesized endogenously. This represents a fundamental gap in understanding DSIP as an endogenous signaling molecule.
The hypothesis that DSIP is the principal endogenous sleep factor — implied by its name — is, in the words of a 2006 PubMed review, extremely poorly documented and still weak. Significant slow-wave sleep promoting activity has been demonstrated with certain artificial DSIP structural analogs but not consistently with native DSIP itself in animal studies.
The majority of DSIP research was conducted between the 1970s and early 2000s with limited independent replication of some key findings in contemporary research settings.
Human clinical data is limited to small studies primarily examining the sleep indication, and results have been mixed.
These limitations do not negate the scientific interest in DSIP as a research compound, but they are important context for any laboratory investigator designing protocols using this peptide.
Current Research Status
DSIP is not approved by the FDA for any indication and has not undergone or completed dedicated regulatory clinical trial programs in the way that compounds such as cagrilintide, retatrutide, or ARA-290 have. It is an endogenous peptide that is studied as a research compound for neuromodulatory, stress-limiting, neuroprotective, and sleep-related applications in preclinical and exploratory human research settings.
Reconstitution Note
DSIP is a peptide compound. Bacteriostatic water is the standard reconstitution solvent for this compound in laboratory research settings. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the DSIP product page: https://roguecompounds.com/product/dsip/